Canaccord analyst William Plovanic raised the firm’s price target on Staar Surgical to $80 from $79 and keeps a Buy rating on the shares. The analyst believes that, by explaining the optionality that EVO offers, surgeons should be able to convert patients into EVO users although admittedly, the EVO procedures remain at a premium to LASIK.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STAA:
- Staar Surgical price target raised to $79 from $76 at Canaccord
- Staar Surgical reports preliminary Q4 revenue $64M, consensus $65.01M
- This Insider Just Bought Staar Surgical (NASDAQ:STAA) Shares Worth $9.1M
- Staar Surgical price target lowered to $67 from $80 at BTIG
- Staar Surgical price target lowered to $85 from $91 at Stephens